1996, incorporated as Harbin Renhuang Pharmaceutical
Stock Co. Ltd.
2001, reorganized from a closely held
limited-liability company to a public limited-liability company
2004, capital was increased to 80,000,000 RMB (about
US$10 million)
2004, named by the city government of Harbin as the
“Outstanding Small Enterprise of Harbin”
2004, Renhuang’s project for Ah City Biotech Medicine
Park (the Ah City Facility) was listed in the supported and
tax-advantaged programs for the development of Northeastern industry by
the National Development and Reform Commission
2004, Renhuang’s process development project of
one-step extraction of Lysozyme enzyme was listed in the “National Torch
Programs” as a key project for the development of high technology
2004, Renhuang’s Ah City manufacturing facility (Ah
City Biotech Medicine Park) and Dongfanghong manufacturing facility were
certified as GMP (“Good Manufacturing Practice”)
2004, Renhuang established the post-doctoral research
working center upon the approval of the government
2006, on May 1, the Company was reorganized to a new company, Harbin
Renhuang Pharmaceutical
Co. Ltd.
2006, on September 7, the Company went public in the
US through a reverse merger and is traded on NASDAQ OTCBB under the
ticker symbol RHGP
supported and
tax-advantaged programs for the development of Northeastern industry by
the National
“National Torch
Programs” as a key project for the development of high technology